MX2008013416A - Medios para inhibir la expresion de cd31. - Google Patents
Medios para inhibir la expresion de cd31.Info
- Publication number
- MX2008013416A MX2008013416A MX2008013416A MX2008013416A MX2008013416A MX 2008013416 A MX2008013416 A MX 2008013416A MX 2008013416 A MX2008013416 A MX 2008013416A MX 2008013416 A MX2008013416 A MX 2008013416A MX 2008013416 A MX2008013416 A MX 2008013416A
- Authority
- MX
- Mexico
- Prior art keywords
- stretch
- nucleotide
- seq
- nucleic acid
- strand
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
La presente invención se refiere a una molécula de ácido nucleico que comprende una estructura de hebra doble, caracterizada por que la estructura de hebra doble comprende una primera hebra y una segunda hebra, en donde la primera hebra comprende una primera extensión de nucleótidos contiguos y la primera extensión es al menos parcialmente complementaria con un ácido nucleico objetivo, y en donde la segunda hebra comprende una segunda extensión de nucleótidos contiguos y la segundo extensión es al menos parcialmente complementaria a la primera extensión, en donde la primera extensión comprende una secuencia de ácido nucleico la cual es al menos parcialmente complementaria a una secuencia de centro de nucleótido de la secuencia de ácido nucleico de acuerdo con SEQ. ID. No. 1, en donde la secuencia de centro de nucleótido comprende la secuencia de nucleótidos de las posiciones de nucleótidos 1277 a 1295 de SEQ. ID No. 1; de las posiciones de nucleótidos 2140 a 2158 de SEQ. ID No. 1; de las posiciones de nucleótidos de 2391 a 2409 de SEQ. ID No. 1; y en donde la primera extensión es además al menos parcialmente complementaria a una región que procede del extremo 5' de la secuencia de centro de nucleótido y/o a una región después del extremo 3' de la secuencia de centro de nucleótido.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06008208 | 2006-04-20 | ||
PCT/EP2007/003495 WO2007121946A2 (en) | 2006-04-20 | 2007-04-20 | Means for inhibiting the expression of cd31 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2008013416A true MX2008013416A (es) | 2008-11-12 |
Family
ID=38229748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2008013416A MX2008013416A (es) | 2006-04-20 | 2007-04-20 | Medios para inhibir la expresion de cd31. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20090252783A1 (es) |
EP (1) | EP2007890A2 (es) |
JP (1) | JP2009535018A (es) |
KR (1) | KR20090004984A (es) |
CN (1) | CN101426915A (es) |
AU (1) | AU2007241369A1 (es) |
BR (1) | BRPI0711626A2 (es) |
CA (1) | CA2649020A1 (es) |
MX (1) | MX2008013416A (es) |
RU (1) | RU2008145782A (es) |
WO (1) | WO2007121946A2 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1830888B1 (en) | 2004-12-27 | 2015-08-05 | Silence Therapeutics GmbH | Lipid complexes coated with peg and their use |
WO2010110314A1 (ja) * | 2009-03-27 | 2010-09-30 | 協和発酵キリン株式会社 | 核酸を含有する肺高血圧症治療剤 |
CA3043768A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5479663B2 (ja) * | 2002-12-20 | 2014-04-23 | セレラ コーポレーション | 心筋梗塞に関連する遺伝的多型、その検出方法および使用 |
CN1968714B (zh) * | 2004-05-05 | 2013-10-16 | 赛伦斯治疗公司 | 脂质、脂质复合物及其应用 |
AU2005277186A1 (en) * | 2004-08-20 | 2006-03-02 | The Johns Hopkins University | Methods for treatment of angiogenesis |
-
2007
- 2007-04-20 RU RU2008145782/13A patent/RU2008145782A/ru not_active Application Discontinuation
- 2007-04-20 KR KR1020087025259A patent/KR20090004984A/ko not_active Application Discontinuation
- 2007-04-20 WO PCT/EP2007/003495 patent/WO2007121946A2/en active Application Filing
- 2007-04-20 BR BRPI0711626-8A patent/BRPI0711626A2/pt not_active IP Right Cessation
- 2007-04-20 MX MX2008013416A patent/MX2008013416A/es not_active Application Discontinuation
- 2007-04-20 JP JP2009505788A patent/JP2009535018A/ja active Pending
- 2007-04-20 EP EP07724431A patent/EP2007890A2/en not_active Withdrawn
- 2007-04-20 US US12/297,592 patent/US20090252783A1/en not_active Abandoned
- 2007-04-20 AU AU2007241369A patent/AU2007241369A1/en not_active Abandoned
- 2007-04-20 CA CA002649020A patent/CA2649020A1/en not_active Abandoned
- 2007-04-20 CN CNA2007800140202A patent/CN101426915A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2007890A2 (en) | 2008-12-31 |
AU2007241369A1 (en) | 2007-11-01 |
CN101426915A (zh) | 2009-05-06 |
WO2007121946A2 (en) | 2007-11-01 |
BRPI0711626A2 (pt) | 2011-12-06 |
US20090252783A1 (en) | 2009-10-08 |
WO2007121946A3 (en) | 2008-01-10 |
KR20090004984A (ko) | 2009-01-12 |
CA2649020A1 (en) | 2007-11-01 |
JP2009535018A (ja) | 2009-10-01 |
RU2008145782A (ru) | 2010-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009000654A (es) | Medios para inhibir la expresion de la cinasa de proteina 3. | |
MX2010004452A (es) | Acido ribonucleico de doble cadena modificado con lipidos que tienen un potente efecto de interferencia de acido ribonucleico. | |
WO2011056005A3 (ko) | 안티센스 가닥에 의한 오프-타겟 효과를 최소화한 신규한 siRNA 구조 및 그 용도 | |
AU2008339215A8 (en) | Novel siRNA structure for minimizing off-target effects and relaxing saturation of RNAi machinery and the use thereof | |
WO2008036933A3 (en) | Compositions and methods for inhibiting expression of the hamp gene | |
WO2007051045A3 (en) | Compositions and methods for inhibiting expression of huntingtin gene | |
WO2009035303A3 (en) | Bacteriophage or lytic protein derived from the bacteriophage which effective for treatment of staphylococcus aureus biofilm | |
WO2007056326A3 (en) | Compositions and methods for inhibiting expression of nav1.8 gene | |
NZ585327A (en) | Lna antagonists targeting the androgen receptor | |
IN2012DN00403A (es) | ||
WO2008008719A3 (en) | Compositions and methods for inhibiting expression of the myc gene | |
WO2007134161A3 (en) | Compositions and methods for inhibiting expression of the pcsk9 gene | |
NZ563845A (en) | RNAi sequences against the Influenza A segment 1 PB2 gene and uses thereof as anti-viral therapeutic | |
WO2008116860A3 (en) | Dsrna compositions and methods for treating hpv infections | |
WO2007128477A3 (en) | SHORT INTERFERING RIBONUCLEIC ACID (siRNA) FOR ORAL ADMINISTRATION | |
MX2009000656A (es) | Acidos nucleicos que se fijan a sdf-i. | |
SG170780A1 (en) | Compositions and methods for inhibiting expression of eg5 gene | |
MX351107B (es) | Acidos nucleicos que se enlazan con mcp-1. | |
MX2010003109A (es) | Acidos nucleicos de enlace c5a. | |
WO2007127919A3 (en) | Compositions and methods for inhibiting expression of a gene from the jc virus | |
WO2010060967A3 (en) | Compositions and methods for treating retrovirus infections | |
WO2010006973A3 (en) | Compositions and methods for inhibiting expression of tgf-beta receptor genes | |
EP3040423A3 (en) | Microrna and uses thereof | |
WO2006102970A3 (en) | Modified short interfering rna | |
NZ604094A (en) | Double stranded rna compounds to rhoa and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |